Folate vs folic acid: does the difference actually matter?
The terms folate and folic acid are routinely used interchangeably in supplement marketing, on food labels, and in general health writing. They are not the same compound. The distinction is metabolically meaningful, clinically relevant in some populations, and frequently misrepresented in both directions: either dismissed as irrelevant or inflated into a reason to fear standard folic acid supplementation. Neither framing serves people well.
This article sets out what the difference actually is, what the evidence says about whether it matters for different situations, and what a reasonable conclusion looks like for the most common scenarios.
What is the difference between folate and folic acid?
Folate is the umbrella term for a group of water-soluble B vitamins (B9) that occur naturally in food. Leafy greens, legumes, and liver contain various natural folate forms, primarily as polyglutamate conjugates that require enzymatic conversion in the gut before absorption.
Folic acid is a specific synthetic compound the fully oxidised, stable form used in supplements and food fortification. It does not exist in meaningful amounts in nature. Folic acid has higher bioavailability than food folate under fasting conditions, which was one of the reasons it became the preferred form for supplementation programmes and mandatory grain fortification introduced in many countries from the late 1990s onwards.
Methylfolate (5-methyltetrahydrofolate, or 5-MTHF) is the active circulating form that cells actually use. It is what both food folate and folic acid are ultimately converted to. Methylfolate is available as a supplement in its own right, sold under several branded preparations.
The key metabolic difference is in the conversion pathway. Folic acid, being synthetic and oxidised, requires an enzyme called dihydrofolate reductase (DHFR) to begin conversion, followed by several further steps including a reaction catalysed by the enzyme MTHFR (methylenetetrahydrofolate reductase), before reaching the active 5-MTHF form. Methylfolate supplements bypass most of this conversion entirely and enter circulation as the active form without requiring MTHFR activity.
Why does the MTHFR question keep coming up?
The gene MTHFR encodes the enzyme responsible for a critical step in folate conversion. A common variant in this gene, known as C677T, reduces enzyme activity in a dose-dependent way. Individuals who carry two copies of this variant (homozygous TT genotype) have MTHFR enzyme activity approximately 70 per cent lower than those without the variant. Those with one copy (heterozygous CT genotype) have activity roughly 35 per cent lower. The C677T TT genotype is not rare: homozygous frequency ranges from approximately 5 to 15 per cent depending on the population, with higher rates in some Southern European and Latin American populations (Obeid et al., 2018, Nutrients).
This is a real biochemical difference with measurable consequences. TT homozygotes tend to have higher plasma homocysteine and lower red cell folate at equivalent dietary intakes compared to people without the variant, particularly when overall folate status is marginal. These differences are well-documented in population genetics literature and are consistent with the functional consequence of reduced MTHFR activity.
The logic behind recommending methylfolate for TT individuals is that because folic acid conversion to 5-MTHF depends on MTHFR as a rate-limiting step, a form that bypasses this step should reach active status more reliably in people with reduced enzyme function. This is mechanistically coherent and represents a mechanism-driven inference rather than an outcome-driven recommendation.
The evidence gap is in clinical outcomes. There are no adequately powered randomised controlled trials comparing methylfolate directly to folic acid on patient-important endpoints, such as neural tube defect prevention rates or pregnancy outcomes specifically in MTHFR TT individuals. There is no evidence that methylfolate improves clinical outcomes compared to folic acid even in this genotype. The mechanistic case is well-supported; the direct outcomes evidence to confirm clinical superiority does not yet exist. Major guidelines in the UK (NICE), US (ACOG), and across Europe do not recommend routine MTHFR genotyping before initiating periconceptional folate supplementation, and none specify methylfolate over folic acid as a standard recommendation.
Does the form matter for pregnancy?
This is the most practically important context, and the one where the evidence base is strongest and most directly relevant.
The periconceptional folic acid evidence is among the most robust in nutritional medicine. The MRC Vitamin Study Research Group (1991, Lancet; n = 1,817, women with a prior NTD-affected pregnancy) found a 72 per cent reduction in NTD recurrence (RR 0.28, 95% CI 0.12 to 0.71) in the folic acid group compared to control. This is one of the largest effect sizes in the nutritional supplementation literature. Czeizel and Dudas (1992, NEJM; n = 4,753) demonstrated significant first-occurrence NTD prevention with 0.8 mg folic acid, with no cases in the treatment group against six in controls. Population-level data from countries that introduced mandatory folic acid fortification including a documented reduction in NTD prevalence in the United States following grain fortification in 1998 provided consistent corroboration. This body of evidence established folic acid specifically as the supplemental form with demonstrated preventive efficacy, and the standard clinical recommendation of 400 to 800 mcg daily before conception and through the first 12 weeks reflects that evidence base.
There are no equivalent-scale trials showing that methylfolate is inferior to folic acid for neural tube defect prevention. There are also no equivalent-scale trials establishing it as equivalent or superior. The absence of large comparative trials means the question of whether methylfolate could achieve the same prevention rates as folic acid remains open, though there is no mechanistic reason to expect it would not, the issue is evidentiary, not biological.
For most women planning pregnancy, folic acid at standard doses is what public health guidance is built on and remains the appropriate default. For women who know they carry the MTHFR C677T TT genotype, methylfolate is a mechanistically well-reasoned choice, and a number of clinicians acknowledge it as a reasonable alternative. The important framing is that this is a mechanism-informed decision in the absence of comparative outcome data, not a clinically established superiority. The practical concern in TT homozygotes using folic acid is not that conversion fails entirely. Residual MTHFR activity remains even in TT individuals, but that conversion efficiency is meaningfully reduced, particularly when folate status is marginal.
Women with a prior pregnancy affected by a neural tube defect are typically advised to supplement at 5 mg daily, a high-dose folic acid recommendation. Long-term safety data on high-dose methylfolate at equivalent doses is limited, and the 5 mg recommendation remains specific to folic acid in current guidance. More broadly, chronic high-dose folate supplementation outside of a clear clinical indication, whether folic acid or methylfolate is not well-supported by evidence of benefit, and the long-term safety profile of high-dose methylfolate specifically has not been established in large human trials.
What about unmetabolised folic acid?
At higher supplemental doses, the conversion pathway for folic acid becomes capacity-limited. The result is that unmetabolised folic acid (UMFA) appears in circulation. This does not occur with methylfolate because it does not require conversion. Bailey and Ayling (2009, Proceedings of the National Academy of Sciences) characterised the saturation kinetics of the DHFR step and demonstrated that UMFA accumulates in plasma at doses above approximately 200 to 300 mcg - doses routinely exceeded by standard supplements and fortified foods in combination.
The biological significance of circulating UMFA is an active research question with genuinely uncertain clinical implications. Some studies have raised concerns about potential effects on natural killer cell function, and some observational data has suggested associations with cancer outcomes, though these findings are inconsistent and causality has not been established. The current evidence does not demonstrate harm at doses within the upper tolerable intake of 1,000 mcg per day for adults, but it is not sufficient to exclude long-term effects, the studies conducted to date have not been powered or designed to detect them. No regulatory body has moved to revise upper intake recommendations on the basis of current UMFA data, and the research continues.
The practical implication is a reason to avoid routinely exceeding 1,000 mcg folic acid daily without clinical indication, and a reasonable basis for preferring methylfolate for those specifically concerned about UMFA, while being clear that this is a precautionary rather than an evidence-of-established-harm rationale.
Does the form matter for general supplementation outside of pregnancy?
For healthy adults supplementing for general nutritional adequacy, the form difference is less clinically significant than in pregnancy, though the evidence base for drawing strong equivalence conclusions is also thin.
At standard supplemental doses, the folic acid conversion pathway functions in the large majority of people without MTHFR TT genotype. There is no evidence demonstrating a clinically meaningful difference between folic acid and methylfolate in this population, and no comparative trials have directly established equivalence or superiority, the head-to-head evidence base is limited. There is also no evidence that methylfolate improves clinical outcomes compared to folic acid, including in individuals with the MTHFR TT genotype.
In individuals with the MTHFR TT genotype, there is a reasonable mechanistic case for preferring methylfolate even outside pregnancy, since the conversion efficiency rationale applies regardless of the specific outcome being targeted. Whether this preference translates into meaningfully different health outcomes in otherwise healthy, replete adults with TT genotype has not been established in clinical trials.
The B12 masking issue applies to both forms
One safety consideration that applies to folate supplementation regardless of form is the potential to mask vitamin B12 deficiency. Any metabolically active folate form can correct the haematological presentation of B12 deficiency - the enlarged red blood cells that flag deficiency on a standard blood count while leaving neurological damage from B12 deficiency to progress undetected. This is the most clinically important safety consideration in folate supplementation, and the regulatory upper limit of 1,000 mcg per day for folic acid exists specifically because of this masking risk rather than direct folate toxicity.
The risk is most relevant for older adults, people following plant-based diets, and anyone with risk factors for B12 malabsorption. The concern is often attributed specifically to folic acid in consumer content, but the masking mechanism applies to methylfolate as well. Any active folate form can correct megaloblastic anaemia. B12 status should be assessed in at-risk individuals before beginning high-dose folate supplementation of any form.
What can reasonably be concluded
The form distinction between folate, folic acid, and methylfolate is real and not merely a marketing conversation. Whether it changes what an individual should take depends on context.
For women planning pregnancy without known MTHFR status, standard folic acid at 400 to 800 mcg is the evidence-based recommendation, anchored in the MRC Vitamin Study and subsequent data. There is no established clinical need to test for MTHFR before beginning supplementation. For women who know they carry the MTHFR C677T TT genotype, methylfolate is a mechanistically well-reasoned choice and a defensible preference but this is a mechanism-informed decision, not one backed by comparative outcome trials showing superiority. For general supplementation outside of pregnancy in people without known MTHFR TT genotype, the evidence does not support paying a premium for methylfolate over folic acid at standard doses. For anyone choosing methylfolate on precautionary grounds without knowing their genotype, the choice is not unreasonable but the basis is precautionary rather than evidence-led.
The degree of alarm circulating online about folic acid being harmful or effectively blocked in people with MTHFR variants is not in proportion to what the clinical evidence shows. Conversion efficiency is reduced in TT individuals, not eliminated, and the clinical consequences in most everyday contexts are modest. The biochemical concern is legitimate; the level of alarm is not matched by clinical outcome data.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.
Key references
MRC Vitamin Study Research Group (1991). Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet, 338(8760), 131--137. doi:10.1016/0140-6736(91)90133-A
Czeizel AE & Dudas I (1992). Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. NEJM, 327(26), 1832--1835. doi:10.1056/NEJM199212243272602
Bailey SW & Ayling JE (2009). The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proceedings of the National Academy of Sciences, 106(36), 15424--15429. doi:10.1073/pnas.0902072106
Obeid R et al. (2018). Folate and methylation -- implications for health. Nutrients, 10(11), 1677. doi:10.3390/nu10111677
For detailed trial data, effect sizes, and population-specific evidence ratings, see the Folate entry in the Evidentia library. For the relationship between folate and B12 status, see the Vitamin B12 entry.